Sintilimab Plus Nanoparticle Polymeric Micellar Paclitaxel and S-1 as First-Line Treatment in HER2-Negative Advanced Gastric Cancer: A Real-World Study
The combination of sintilimab, NPMP and S-1 demonstrates promising antitumor effects and controllable toxicity as first-line treatment in patients with HER2-negative with AGC.
Authors
- AI-GUO CAO
- Yu-Qing Cao
- Fei-Yu Wang
- Ying Peng
- Meng Song
- Xiang-Ming Huang
- Jie Cao
- Xin-En Huang
Institutions
- Nanjing University of Chinese Medicine (CN)
- Taixing People's Hospital (CN)
- Nanjing Brain Hospital (CN)
- Jiangsu Cancer Hospital (CN)
Publication Details
- Journal
- Journal of Gastrointestinal Cancer
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1007/s12029-025-01390-x
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00